Europe Irritable Bowel Syndrome Treatment Market Industry Trends and Forecast to 2034: Segmented by (Type, Treatment, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Europe · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$624.6 MnPlaceholder estimate
Estimate 2025$667.0 Mn19.1% of the global market
Projected 2034$1.21 Bn 80.8%Adds $538.8 Mn over 9 forecast years
CAGR 2025–20346.8%Faster than 51% of 183 Pharmaceuticals markets here
Key players5
Europe is 19.06% of the global market.
Among regions, the largest is North America at $1.62 Bn.
34 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Europe Irritable Bowel Syndrome Treatment Market Analysis Executive Summary
Irritable bowel syndrome treatments ease belly pain, bloating, diarrhoea and constipation with medicines, diet and gut-directed therapy.
Key segments of the irritable Bowel Syndrome Treatment market include type (IBS-D, IBS-C and IBS-M) and treatment (Prescription Drugs, OTC Products and Probiotics).
Europe Irritable Bowel Syndrome Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Europe Irritable Bowel Syndrome Treatment Market Dynamics
Market Growth Drivers
Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the irritable Bowel Syndrome Treatment market.
Opportunity
Microbiome-based treatments, earlier testing and digital gut-health programmes give the irritable Bowel Syndrome Treatment market room to grow.
Market Restraints
Late diagnosis, stigma, limited specialist access and high prices of new medicines hold back the irritable Bowel Syndrome Treatment market.
Competitive Landscape for Irritable Bowel Syndrome Treatment Market in Europe
The irritable Bowel Syndrome Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Irritable Bowel Syndrome Treatment Market in Europe
Irritable Bowel Syndrome Treatment in Europe: rules, payment and research
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6], MHRA (UK)[7], CBG-MEB (Netherlands)[8], FAMHP (Belgium)[9], Swissmedic (Switzerland)[10], Läkemedelsverket (Sweden)[11], Danish Medicines Agency (Denmark)[12], URPL (Poland)[13] and TITCK (Turkey)[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[15] ClinicalTrials.gov lists 34 studies on Irritable Bowel Syndrome Treatment that are recruiting, active or about to start in Europe.[16]
[16]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for irritable Bowel Syndrome Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Type
4.2 By Treatment
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 AbbVie
7.2 Ironwood Pharmaceuticals
7.3 Bausch Health
7.4 Ardelyx
7.5 Mahana Therapeutics
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The irritable Bowel Syndrome Treatment market can be segmented based on various criteria, including type, treatment and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Irritable Bowel Syndrome Treatment right now, from free public sources.
Clinical trials
34 active trials in UK, Germany, France, Italy, Spain, Netherlands, Belgium, Switzerland, Sweden, Denmark, Poland, Turkey and Russia
Recruiting, about to start, or running now. Counted across the 13 countries we report on in Europe.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Irritable Bowel Syndrome Treatment market in Europe?
Placeholder estimate: about $667.0 Mn in 2025, rising to about $1.21 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Irritable Bowel Syndrome Treatment market in Europe growing?
Placeholder estimate: about 6.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Irritable Bowel Syndrome Treatment market report cover?
The report splits the market by type (IBS-D, IBS-C, IBS-M), treatment (Prescription Drugs, OTC Products, Probiotics, Digital Therapy) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Irritable Bowel Syndrome Treatment market?
Key players include AbbVie Inc., Ironwood Pharmaceuticals, Bausch Health, Ardelyx and Mahana Therapeutics.
What is driving the Irritable Bowel Syndrome Treatment market?
Rising rates of gut and liver disease linked to diet, obesity and alcohol, more screening and new treatments are driving the irritable Bowel Syndrome Treatment market.
Who regulates Irritable Bowel Syndrome Treatment in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on Irritable Bowel Syndrome Treatment are running in Europe?
34 studies are recruiting, active or about to start in Europe, counted across the 13 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on Irritable Bowel Syndrome Treatment?
PubMed lists 15 papers on Irritable Bowel Syndrome Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.